The therapeutic potential of IGF-I in skeletal muscle repair

Trends in Endocrinology and Metabolism

Volumn 24, Issue 6, 2013, Pages 310-319

  Song, Yao Hua ^a   Song, Jenny L ^a   Delafontaine, Patrice ^b   Godard, Michael P ^c  

^a SOOCHOW UNIVERSITY   (China)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CENTRAL MISSOURI   (United States)

Author keywords

IGF I; Muscle wasting; Satellite cell

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MACROGOL; MAMMALIAN TARGET OF RAPAMYCIN; MECHANO GROWTH FACTOR; MICROSPHERE; MITOGEN ACTIVATED PROTEIN KINASE; MYOSTATIN; PARVOVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; S6 KINASE; SMAD3 PROTEIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG;

ADAPTATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; CACHEXIA; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); COLORECTAL ADENOMA; DIABETIC NEUROPATHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; GROWTH HORMONE RELEASE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; KENNEDY DISEASE; MILD COGNITIVE IMPAIRMENT; MITOGENESIS; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE MASS; MUSCLE SATELLITE CELL; MUSCLE STRENGTH; NERVE FIBER GROWTH; NEUROMUSCULAR DISEASE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW; SARCOPENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE REPAIR; VASCULAR DISEASE;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SKELETAL; REGENERATION; SATELLITE CELLS, SKELETAL MUSCLE;

EID: 84878252803     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.03.004     Document Type: Review

References (97)

1. Serra C., et al. The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle. Endocrinology 2011, 152:193-206.
2. Clemmons D.R. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol. Metab. 2009, 20:349-356.
3. Nindl B.C., et al. Circulating IGF-I is associated with fitness and health outcomes in a population of 846 young healthy men. Growth Horm. IGF Res. 2011, 21:124-128.
4. Hamilton D.L., et al. A limited role for PI(3,4,5)P3 regulation in controlling skeletal muscle mass in response to resistance exercise. PLoS ONE 2010, 5:e11624.
5. Hornberger T.A. Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle. Int. J. Biochem. Cell Biol. 2011, 43:1267-1276.
6. Spangenburg E.E., et al. A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. J. Physiol. 2008, 586:283-291.
7. Flueck M., Goldspink G. Point:Counterpoint: IGF is/is not the major physiological regulator of muscle mass. Counterpoint: IGF is not the major physiological regulator of muscle mass. J. Appl. Physiol. 2010, 108:1821-1823.
8. Alzhanov D.T., et al. Long range interactions regulate Igf2 gene transcription during skeletal muscle differentiation. J. Biol. Chem. 2010, 285:38969-38977.
9. Gardner S., et al. TGF-beta inhibits muscle differentiation by blocking autocrine signaling pathways initiated by IGF-II. Mol. Endocrinol. 2011, 25:128-137.
10. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008, 23:160-170.
11. Eley H.L., et al. Role of the dsRNA-dependent protein kinase (PKR) in the attenuation of protein loss from muscle by insulin and insulin-like growth factor-I (IGF-I). Mol. Cell. Biochem. 2008, 313:63-69.
12. Middlekauff H.R. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ. Heart Fail. 2010, 3:537-546.
13. Tisdale M.J. Is there a common mechanism linking muscle wasting in various disease types?. Curr. Opin. Support. Palliat. Care 2007, 1:287-292.
14. Kandarian S. The molecular basis of skeletal muscle atrophy - parallels with osteoporotic signaling. J. Musculoskelet. Neuronal Interact. 2008, 8:340-341.
15. Cheema U., et al. Mechanical signals and IGF-I gene splicing in vitro in relation to development of skeletal muscle. J. Cell. Physiol. 2005, 202:67-75.
16. Sandona D., et al. Adaptation of mouse skeletal muscle to long-term microgravity in the MDS mission. PLoS ONE 2012, 7:e33232.
17. Koncarevic A., et al. The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension. FASEB J. 2007, 21:427-437.
18. Shi X., Garry D.J. Muscle stem cells in development, regeneration, and disease. Genes Dev. 2006, 20:1692-1708.
19. Hill M., et al. Muscle satellite (stem) cell activation during local tissue injury and repair. J. Anat. 2003, 203:89-99.
20. Petrella J.K., et al. Potent myofiber hypertrophy during resistance training in humans is associated with satellite cell-mediated myonuclear addition: a cluster analysis. J. Appl. Physiol. 2008, 104:1736-1742.
21. Conboy I.M., et al. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003, 302:1575-1577.
22. Carlson M.E., et al. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 2008, 454:528-532.
23. Arthur S.T., Cooley I.D. The effect of physiological stimuli on sarcopenia; impact of Notch and Wnt signaling on impaired aged skeletal muscle repair. Int. J. Biol. Sci. 2012, 8:731-760.
24. Collins C.A., et al. A population of myogenic stem cells that survives skeletal muscle aging. Stem Cells 2007, 25:885-894.
25. Shavlakadze T., et al. Delayed but excellent myogenic stem cell response of regenerating geriatric skeletal muscles in mice. Biogerontology 2010, 11:363-376.
26. Alsharidah M., et al. Primary human muscle precursor cells obtained from young and old donors produce similar proliferative, differentiation and senescent profiles in culture. Aging Cell 2013, 10.1111/acel.12051.
27. McGeachie J.K. The fate of proliferating cells in skeletal muscle after denervation or tenotomy: an autoradiographic study. Neuroscience 1985, 15:499-506.
28. Abbatecola A.M., et al. Pulse wave velocity is associated with muscle mass decline: Health ABC study. Age (Dordr.) 2012, 34:469-478.
29. Thum T., et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ. Res. 2007, 100:434-443.
30. Barbieri M., et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E481-E487.
31. Lang T., et al. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos. Int. 2010, 21:543-559.
32. 2+-dependent skeletal muscle contraction in senescent mice. Exp. Gerontol. 2007, 42:309-319.
33. Haddad F., Adams G.R. Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. J. Appl. Physiol. 2006, 100:1188-1203.
34. Burks T.N., et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci. Transl. Med. 2011, 3:82ra37.
35. Giovannini S., et al. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. Mech. Ageing Dev. 2008, 129:593-601.
36. Giannoulis M.G., et al. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?. Endocr. Rev. 2012, 33:314-377.
37. Dobrowolny G., et al. Muscle expression of a local IGF-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005, 168:193-199.
38. Saenger S., et al. Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity. Amyotroph. Lateral Scler. 2012, 13:418-429.
39. Van Hoecke A., et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 2012, 18:1418-1422.
40. Palazzolo I., et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009, 63:316-328.
41. Hua Y., et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011, 478:123-126.
42. Bosch-Marce M., et al. Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Hum. Mol. Genet. 2011, 20:1844-1853.
43. Simon C.M., et al. Ciliary neurotrophic factor-induced sprouting preserves motor function in a mouse model of mild spinal muscular atrophy. Hum. Mol. Genet. 2010, 19:973-986.
44. Pun S., et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 2006, 9:408-419.
45. Patel K., et al. Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy. Acta Myol. 2005, 24:230-241.
46. Noguchi S. The biological function of insulin-like growth factor-I in myogenesis and its therapeutic effect on muscular dystrophy. Acta Myol. 2005, 24:115-118.
47. Secco M., et al. Systemic delivery of human mesenchymal stromal cells combined with IGF-1 enhances muscle functional recovery in LAMA2(dy/2j) dystrophic mice. Stem Cell Rev. 2013, 9:93-109.
48. Gehrig S.M., et al. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Exp. Physiol. 2008, 93:1190-1198.
49. Bentzinger C.F., et al. Extrinsic regulation of satellite cell specification. Stem Cell Res. Ther. 2010, 1:27.
50. Gehrig S.M., et al. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Growth Horm. IGF Res. 2012, 22:69-75.
51. Lynch G.S., et al. IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. Neuromuscul. Disord. 2001, 11:260-268.
52. Chu Q., et al. Systemic Insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Mol. Ther. 2008, 16:1400-1408.
53. Acharyya S., Guttridge D.C. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin. Cancer Res. 2007, 13:1356-1361.
54. Sanders P.M., et al. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer 2005, 93:425-434.
55. Russell S.T., et al. Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 2006, 231:290-294.
56. Zhou X., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
57. Trendelenburg A.U., et al. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 2009, 296:C1258-C1270.
58. Schmidt K., et al. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. J. Cachexia Sarcopenia Muscle 2011, 2:105-109.
59. Penna F., et al. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?. Int. J. Cancer 2010, 127:1706-1717.
60. Middlekauff H.R., Sinoway L.I. Increased mechanoreceptor stimulation explains the exaggerated exercise pressor reflex seen in heart failure. J. Appl. Physiol. 2007, 102:492-494. discussion 496.
61. Song Y.H., et al. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Invest. 2005, 115:451-458.
62. Serose A., et al. Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamster. Basic Res. Cardiol. 2005, 100:161-170.
63. Godard M.P., et al. Skeletal muscle molecular alterations precede whole-muscle dysfunction in NYHA Class II heart failure patients. Clin. Interv. Aging 2012, 7:489-497.
64. Tracy B.L., et al. Muscle quality. II. Effects of strength training in 65- to 75-yr-old men and women. J. Appl. Physiol. 1999, 86:195-201.
65. Hammers D.W., et al. Impairment of IGF-I expression and anabolic signaling following ischemia/reperfusion in skeletal muscle of old mice. Exp. Gerontol. 2011, 46:265-272.
66. Hammers D.W., et al. Controlled release of IGF-I from a biodegradable matrix improves functional recovery of skeletal muscle from ischemia/reperfusion. Biotechnol. Bioeng. 2012, 109:1051-1059.
67. Pelosi L., et al. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J. 2007, 21:1393-1402.
68. Sorenson E.J., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.
69. Howe C.L., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2009, 73:1247. author reply 1247-1248.
70. Kandalla P.K., et al. Mechano growth factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech. Ageing Dev. 2011, 132:154-162.
71. Malerba F., et al. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin. Drug Deliv. 2011, 8:1277-1296.
72. Craft S., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
73. Garbayo E., et al. Effective GDNF brain delivery using microspheres - a promising strategy for Parkinson's disease. J. Control. Release 2009, 135:119-126.
74. Borselli C., et al. Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3287-3292.
75. Gambassi G., et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch. Intern. Med. 2000, 160:53-60.
76. Gao Y., et al. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int. J. Cancer 2012, 131:E105-E113.
77. Roddam A.W., et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann. Intern. Med. 2008, 149:461-471. W483-468.
78. Nystrom G., et al. Local insulin-like growth factor I prevents sepsis-induced muscle atrophy. Metabolism 2009, 58:787-797.
79. Palazzolo I., et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum. Mol. Genet. 2007, 16:1593-1603.
80. Nichols N.L., et al. Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis. Am. J. Respir. Crit. Care Med. 2013, 187:535-542.
81. Haddad F., et al. Isometric resistance exercise fails to counteract skeletal muscle atrophy processes during the initial stages of unloading. J. Appl. Physiol. 2006, 100:433-441.
82. Sandri M., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
83. Yamaguchi A., et al. Expression of specific IGFBPs is associated with those of the proliferating and differentiating markers in regenerating rat plantaris muscle. J. Physiol. Sci. 2012, 63:71-77.
84. Rehfeldt C., et al. Increased fat mass, decreased myofiber size, and a shift to glycolytic muscle metabolism in adolescent male transgenic mice overexpressing IGFBP-2. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E287-E298.
85. Tripathi G., et al. IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo. FASEB J. 2009, 23:2616-2626.
86. Velloso C.P., Harridge S.D. Insulin-like growth factor-I E peptides: implications for aging skeletal muscle. Scand. J. Med. Sci. Sports 2010, 20:20-27.
87. Matheny R.W., Nindl B.C. Loss of IGF-IEa or IGF-IEb impairs myogenic differentiation. Endocrinology 2011, 152:1923-1934.
88. Barton E.R., et al. The insulin-like growth factor (IGF)-I E-peptides are required for isoform-specific gene expression and muscle hypertrophy after local IGF-I production. J. Appl. Physiol. 2010, 108:1069-1076.
89. Matheny R.W., et al. Minireview: mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 2010, 151:865-875.
90. Ophoff J., et al. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 2009, 150:3558-3566.
91. Lopez-Menduina M., et al. Systemic IGF-I administration attenuates the inhibitory effect of chronic arthritis on gastrocnemius mass and decreases atrogin-1 and IGFBP-3. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299:R541-R551.
92. Hunter R.B., Kandarian S.C. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J. Clin. Invest. 2004, 114:1504-1511.
93. Mourkioti F., et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Invest. 2006, 116:2945-2954.
94. Van Gammeren D., et al. The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy. FASEB J. 2009, 23:362-370.
95. Morissette M.R., et al. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am. J. Physiol. Cell Physiol. 2009, 297:C1124-C1132.
96. Lee S.J., et al. Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E2353-E2360.
97. Amthor H., et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1835-1840.